Cytokinetics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
350 Oyster Point Blvd, South San Francis...Phone Number
(650) 624-3000Website
www.cytokinetics.comRevenue
$105.8 MillionStock Symbol
CYTKIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
1
2
1
1
1
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Founded in South San Francisco, California, by pioneers in the field of muscle biology, we have been leveraging our scientific expertise to develop new medicines for patients.Explore more
Cytokinetics Org Chart
JC
Global Executive Director, Supply Chain
BL
Head Senior Director, Regulatory Labeling
BP
Senior Director, Trade & Distribution
JV
Head Senior Director, Chemical Development & ...
JB
Senior Director, Project Management
CB
Senior Director, Facilities EH & S
KC
Director
IK
Director, Program Management
FG
Director, Operational Excellence
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cytokinetics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cytokinetics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cytokinetics
Earning: See what the market has to say on Cytokinetics recently announced quarterly report
Check out if Cytokinetics is spiking on competitors!
Product Launch: Get notified when Cytokinetics launches new products
Cytokinetics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Cytokinetics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Cytokinetics has new funding data
Recommended Actions
Reach out to Masked Content who joined Cytokinetics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Cytokinetics
Compare insights from companies similar to Cytokinetics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cytokinetics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cytokinetics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cytokinetics.
Cytokinetics financials insights
Gather financial insights about Cytokinetics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2004
Stock Offering
$89.7M
2006
Stock Offering
$33M
2017
Other Financing Round
$100M
Cytokinetics Tech Stack
A closer look at the technologies used by Cytokinetics
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Project
Pharmaceuticals
Cytokinetics News & Media
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%
Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership stake.Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026
Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic CardiomyopathyCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 15, 2026 it granted stock options to purchase an aggregate of 24,784 shares of common stock and 16,429 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting and 2,242 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 12 employees, whoseCytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment
Cytokinetics (NASDAQ:CYTK) is one of the most promising mid-cap stocks to buy according to analysts. On June 1, Cytokinetics announced the first commercial European launch of MYQORZO (aficamten) in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy/oHCM. The launch follows European Commission approval in February and builds on prior regulatory approvals in the US […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cytokinetics
Sign Up For FreeTo access detailed company insights
Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Founded in South San Francisco, California, by pioneers in... Read More
